
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> Hepatology</li><li>- <b>Publication:</b> Publish Ahead of Print (Copyright 2025)</li><li>- <b>DOI:</b> 10.1097/HEP.0000000000001549</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended ALT cutoff for defining 'normal' in males and females for CHB management?</li><li>- In pregnant persons with HBV DNA >200,000 IU/mL, when should TDF/TAF prophylaxis ideally be initiated?</li><li>- For HBeAg-negative individuals who stop NA therapy, what quantitative HBsAg level is associated with a higher likelihood of HBsAg loss?</li><li>- What is the recommended HBV DNA threshold for healthcare workers performing SHEA category III procedures to reduce transmission risk?</li><li>- After HBsAg loss, HCC surveillance is suggested for men who experienced this loss after what age?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Core Concepts of Chronic Hepatitis B (CHB)</strong></summary>
            <div>
                <ul><li>- CHB is a <b>dynamic disease</b> characterized by distinct phases, requiring regular monitoring to guide management changes.</li></ul>
                
        <details>
            <summary><strong>Phases of CHB (See Table 1)</strong></summary>
            <div>
                <ul><li>- Understanding the phase of infection is critical for treatment decisions.</li></ul>
                
        <details>
            <summary><strong>Immune-tolerant</strong></summary>
            <div>
                <ul><li>- <b>HBeAg-positive</b></li><li>- HBV DNA: <q><u>>10,000,000 IU/mL</u></q></li><li>- ALT: Normal (<q><b><35 U/L</b> for males</q>, <q><b><25 U/L</b> for females</q>)</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>HBeAg-positive Immune Active</strong></summary>
            <div>
                <ul><li>- <b>HBeAg-positive</b></li><li>- HBV DNA: <q><u>>20,000 IU/mL</u></q></li><li>- ALT: Elevated <q><b>≥2x ULN</b></q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>HBeAg-negative Immune Active</strong></summary>
            <div>
                <ul><li>- <b>HBeAg-negative</b></li><li>- HBV DNA: <q><u>>2,000 IU/mL</u></q></li><li>- ALT: Elevated <q><b>≥2x ULN</b></q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Inactive</strong></summary>
            <div>
                <ul><li>- <b>HBeAg-negative</b></li><li>- HBV DNA: <q><u><2,000 IU/mL</u></q></li><li>- ALT: <b>Normal</b></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>HBsAg-negative Immune Clearance</strong></summary>
            <div>
                <ul><li>- HBV DNA: <b>Undetectable</b></li><li>- May have antibody to HBsAg (anti-HBs).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Indeterminate Phases ('Grey Zone')</strong></summary>
            <div>
                <ul><li>- Refers to HBsAg-positive persons whose ALT and HBV DNA levels do not meet criteria for immune active, tolerant, or inactive phases.</li><li>- Affects up to <q><b>40%</b></q> of adults with CHB.</li><li>- More common in <b>HBeAg-negative</b> persons.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Disease Severity Assessment</strong></summary>
            <div>
                <ul><li>- Integral for making treatment and surveillance decisions.</li></ul>
                
        <details>
            <summary><strong>Non-invasive Tests</strong></summary>
            <div>
                <ul><li>- Hepatic transient elastography and serum markers (e.g., FIB-4) can be used for fibrosis staging.</li><li>- Elastography generally shows <b>better performance</b> than FIB-4.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Biopsy</strong></summary>
            <div>
                <ul><li>- Infrequently used but is the <b>most accurate</b> method for defining inflammation severity.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Approved Drug Classes</strong></summary>
            <div>
                <ul><li>- Two classes are approved: Peginterferon and Nucleos(t)ide Analogues (NAs).</li></ul>
                
        <details>
            <summary><strong>Peginterferon</strong></summary>
            <div>
                <ul><li>- <b>Rarely used</b> due to limitations in applicability, safety, and tolerability compared to NAs.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Nucleos(t)ide Analogues (NAs)</strong></summary>
            <div>
                <ul><li>- <b>Preferred treatment</b> for CHB.</li></ul>
                
        <details>
            <summary><strong>Preferred NAs</strong></summary>
            <div>
                <ul><li>- <b>Entecavir (ETV)</b></li><li>- <b>Tenofovir disoproxil fumarate (TDF)</b></li><li>- <b>Tenofovir alafenamide (TAF)</b></li><li>- All offer high efficacy, low resistance rates, and are well-tolerated.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Selection Criteria</strong></summary>
            <div>
                <ul><li>- <b>Renal or bone disease:</b> <u>Avoid TDF</u>.</li><li>- <b>Pregnancy:</b> <u>Avoid ETV</u>.</li><li>- <b>HIV coinfection:</b> <u>Avoid ETV</u> unless HIV RNA is suppressed on an existing regimen.</li><li>- <b>Prior lamivudine exposure:</b> <u>Avoid ETV</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Renal Considerations</strong></summary>
            <div>
                <ul><li>- <b>TAF:</b> Not recommended if CrCl is <q><u><15 ml/min</u></q> and not on dialysis.</li><li>- <b>ETV and TDF:</b> Require dose adjustment for renal dysfunction or dialysis.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Goals of Antiviral Treatment</strong></summary>
            <div>
                <ul><li>- <b>Primary Goals:</b> Prevention of progression to cirrhosis, HCC, and liver-related death.</li><li>- <b>Other Goals:</b> Reduce vertical and horizontal transmission, improve quality of life.</li></ul>
                
        <details>
            <summary><strong>Surrogate Endpoints</strong></summary>
            <div>
                <ul><li>- Used as measures of treatment efficacy due to the long-term nature of clinical endpoints.</li></ul>
                
        <details>
            <summary><strong>Virological</strong></summary>
            <div>
                <ul><li>- HBV DNA undetectable</li><li>- HBeAg loss/seroconversion</li><li>- HBsAg loss/seroconversion</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Biochemical & Histological</strong></summary>
            <div>
                <ul><li>- <b>Biochemical:</b> Normal serum ALT.</li><li>- <b>Histological (infrequent):</b> Improvement in necroinflammation by <q>≥2 points</q> with no worsening of fibrosis.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Functional Cure</strong></summary>
            <div>
                <ul><li>- Defined as <b>HBsAg loss</b>.</li><li>- Associated with a reduction in clinical outcomes and long-term durability.</li><li>- Infrequent with current therapies, but higher with peginterferon than NAs.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Shared Decision Making</strong></summary>
            <div>
                <ul><li>- A collaborative process where provider and patient make informed decisions considering clinical evidence and the patient's values, preferences, and circumstances.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Introduction & Background</strong></summary>
            <div>
                <ul><li>- CHB affects ~258 million globally and leads to an estimated <q>1.1 million deaths</q> annually.</li><li>- In the U.S., the estimated burden may be as high as <q>1.8 million</q> people, with half unaware of their diagnosis.</li></ul>
                
        <details>
            <summary><strong>CDC Recommendations</strong></summary>
            <div>
                <ul><li>- <b>Screening:</b> All adults <q>≥18 years</q> at least once; all pregnant persons during each pregnancy.</li><li>- <b>Vaccination:</b> All infants, children <19, adults 19-59, and adults ≥60 with risk factors.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Prioritization</strong></summary>
            <div>
                <ul><li>- <b>Traditionally:</b> Prioritized for those at greatest risk (immune active disease, significant fibrosis).</li><li>- <b>WHO Recommendation:</b> Simplification and expansion of treatment criteria to address high disease burden in low/middle-income countries.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PICO Question 1: Antiviral Strategy in Pregnancy</strong></summary>
            <div>
                <ul><li>- <b>Question:</b> What is the optimal antiviral strategy for HBsAg-positive pregnant individuals with HBV DNA >200,000 IU/ml to prevent mother-to-child transmission (MTCT)?</li></ul>
                
        <details>
            <summary><strong>Recommendation 1</strong></summary>
            <div>
                <ul><li>- For pregnant persons with HBV DNA <b>>200,000 IU/mL</b>, AASLD <u>recommends initiating</u> <b>TDF</b> or <b>TAF</b> at <q>gestational week 28</q> to prevent MTCT.</li><li>- <b>Note:</b> TDF has a more extensive safety record in pregnancy.</li><li>- <b>Strength:</b> Strong; <b>Certainty:</b> Moderate.</li></ul>
                
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>- <b>Continue therapy:</b> If already on TDF or TAF.</li><li>- <b>Switch therapy:</b> If on entecavir or other antivirals, switch to TDF or TAF.</li><li>- <b>Early initiation:</b> Consider earlier start if invasive procedures (e.g., amniocentesis) are anticipated or if there's a high risk of preterm labor.</li><li>- <b>Discontinuation:</b> TDF/TAF can be stopped at delivery if the sole purpose was preventing MTCT.</li></ul>
                
        <details>
            <summary><strong>Special Scenario: HBIG Unavailability</strong></summary>
            <div>
                <ul><li>- If hepatitis B immune globulin (HBIG) for the infant is unavailable, initiate TDF or TAF earlier, at <q>gestational week 16</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Discontinuation Monitoring</strong></summary>
            <div>
                <ul><li>- Monitor HBV DNA and ALT every <q>1-3 months for up to six months</q> for withdrawal flares.</li><li>- <u>Reinitiate treatment</u> for a significant flare (ALT <q>≥5x ULN</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Breastfeeding</strong></summary>
            <div>
                <ul><li>- Breastfeeding is safe for persons on TDF or TAF.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Evidence & Rationale</strong></summary>
            <div>
                <ul><li>- Perinatal transmission occurs in <q>~8-10%</q> of infants despite standard immunoprophylaxis if maternal HBV DNA is >200,000 IU/mL.</li><li>- TDF and TAF are equally effective and safe in reducing MTCT.</li><li>- TDF/TAF are preferred over lamivudine or telbivudine due to lower resistance risk.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PICO Question 2: Antivirals to Reduce Horizontal Transmission</strong></summary>
            <div>
                <ul><li>- <b>Question:</b> Should antiviral therapy be provided to HBsAg-positive persons with viremia who do not meet disease-specific treatment indications to reduce transmission in high-risk scenarios?</li></ul>
                
        <details>
            <summary><strong>Recommendation 2</strong></summary>
            <div>
                <ul><li>- For persons in high-risk scenarios for transmission, AASLD suggests a <b>shared decision-making approach</b> regarding antiviral treatment.</li><li>- <b>Strength:</b> Conditional; <b>Certainty:</b> Very Low.</li></ul>
                
        <details>
            <summary><strong>Implementation Considerations (See Table 2)</strong></summary>
            <div>
                <ul><li>- <b>High-risk scenarios:</b> Unprotected sex with multiple partners, injection drug use with inconsistent harm reduction, living with susceptible household members, certain healthcare procedures.</li><li>- <b>Favoring treatment:</b> If exposed persons are unvaccinated, have inadequate vaccine response, or are immunocompromised.</li><li>- <u>Avoid stigmatizing practices</u>.</li></ul>
                
        <details>
            <summary><strong>Healthcare Workers</strong></summary>
            <div>
                <ul><li>- Workers performing SHEA category III exposure-prone procedures are at higher risk.</li><li>- Antiviral treatment may be required to reduce transmission risk (SHEA suggests maintaining HBV DNA <q><1000 IU/mL</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Cessation</strong></summary>
            <div>
                <ul><li>- Counsel on risks of cessation (e.g., ALT flare).</li><li>- Revisit the decision to continue therapy if transmission risks are no longer high.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Evidence & Rationale</strong></summary>
            <div>
                <ul><li>- Evidence is indirect, from nonrandomized studies in HIV-positive individuals.</li><li>- No reported transmissions from healthcare workers with low/undetectable HBV DNA on therapy.</li><li>- Rationale is based on biological plausibility and high acceptability.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PICO Question 3: Treatment in Immune-Tolerant Phase</strong></summary>
            <div>
                <ul><li>- <b>Question:</b> Should individuals in the immune-tolerant phase start antiviral therapy versus observation?</li></ul>
                
        <details>
            <summary><strong>Recommendation 3</strong></summary>
            <div>
                <ul><li>- For persons in the immune-tolerant phase, AASLD suggests antiviral therapy for those:</li><li>- Over age <q><b>40 years</b></q> OR</li><li>- With significant liver inflammation (≥ grade 2) or fibrosis (≥ F2).</li><li>- For persons under age 40, a <b>shared decision-making</b> approach is suggested.</li><li>- <b>Strength:</b> Conditional; <b>Certainty:</b> Very Low.</li></ul>
                
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>- <b>Accurate identification:</b> Requires persistently normal ALT (<q>35 U/L males, 25 U/L females</q>) with HBV DNA <q>>10^7 IU/mL</q> on ≥2 measurements ≥6 months apart.</li><li>- <b>Fibrosis Assessment:</b> A VCTE cutoff of <q>7 kPa</q> has 83% specificity for identifying ≥F2 fibrosis.</li><li>- <b>Monitoring if untreated:</b> Test HBV DNA and ALT at least every <q>6 months</q> for adolescents and adults.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Evidence & Rationale</strong></summary>
            <div>
                <ul><li>- High HBV DNA is strongly associated with HCC risk.</li><li>- Age over 40 is associated with a higher likelihood of significant histological disease.</li><li>- Treatment effectively suppresses HBV DNA but has limited effect on HBeAg/HBsAg loss in this phase.</li><li>- Only one retrospective study reported a potential reduction in HCC (HR <q>0.23</q>) and mortality (HR <q>0.24</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PICO Question 4: Treatment in HBeAg-Negative Indeterminate Phase</strong></summary>
            <div>
                <ul><li>- <b>Question:</b> Should HBsAg-positive, HBeAg-negative individuals without cirrhosis and in the indeterminate phase start antiviral therapy versus observation?</li></ul>
                
        <details>
            <summary><strong>Recommendation 4</strong></summary>
            <div>
                <ul><li>- AASLD suggests antiviral therapy using a <b>shared decision-making approach</b>, assessing risks and benefits, and re-evaluating the decision at each follow-up visit.</li><li>- <b>Strength:</b> Conditional; <b>Certainty:</b> Very Low.</li></ul>
                
        <details>
            <summary><strong>Implementation Considerations (See Figure 3)</strong></summary>
            <div>
                <ul><li>- <b>Factors favoring treatment:</b> Older age (<q>>40 years</q>), male sex, low normal platelet counts (<q><180 k/mm3</q>).</li><li>- <b>Advanced fibrosis (F3/F4) requires treatment.</b> Non-invasive thresholds include FIB-4 <q>>1.45</q> and VCTE <q>≥8 kPa</q>.</li><li>- <b>Monitoring if untreated:</b> ALT and HBV DNA every <q>3-6 months</q> for the first year, then every 6 months.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Evidence & Rationale</strong></summary>
            <div>
                <ul><li>- Individuals in this phase are at risk of HCC (pooled annual incidence rate of <q>0.32%</q>).</li><li>- A meta-analysis suggested antiviral treatment was associated with a lower incidence of HCC (aIRR <q>0.36</q>).</li><li>- The evidence is of low certainty, and must be balanced against the burden of long-term therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PICO Question 5: Discontinuation of NA Therapy</strong></summary>
            <div>
                <ul><li>- <b>Question:</b> Should HBsAg-positive individuals without cirrhosis on NA therapy for ≥3 years (HBeAg-negative, undetectable HBV DNA) remain on or discontinue therapy?</li></ul>
                
        <details>
            <summary><strong>Recommendation 5</strong></summary>
            <div>
                <ul><li>- AASLD suggests <u><b>not withdrawing</b></u> nucleos(t)ide analogue therapy until <b>HBsAg loss</b> is achieved.</li><li>- <b>Strength:</b> Conditional; <b>Certainty:</b> Very Low.</li></ul>
                
        <details>
            <summary><strong>Implementation Considerations (See Table 3)</strong></summary>
            <div>
                <ul><li>- For persons with a strong desire to stop, engage in shared decision-making.</li></ul>
                
        <details>
            <summary><strong>Strict Criteria to Consider Stopping</strong></summary>
            <div>
                <ul><li>- <b>MUST meet ALL:</b></li><li>- No history of cirrhosis, decompensation, or HCC.</li><li>- HBeAg-negative/anti-HBe positive for <q>≥1 year</q> (if initially positive).</li><li>- HBV DNA undetectable for <q>≥2 years</q>.</li><li>- Quantitative HBsAg level <q><b><100 IU/mL</b></q>.</li><li>- No co-infection with HIV or HDV.</li><li>- Willing to adhere to frequent monitoring.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Withdrawal Monitoring</strong></summary>
            <div>
                <ul><li>- Monitor ALT and HBV DNA every <q>1-3 months</q> for the first 6 months.</li><li>- Then every 3 months for the next 6-12 months.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Criteria for IMMEDIATE Re-treatment</strong></summary>
            <div>
                <ul><li>- <b>Meet ANY ONE of the following:</b></li><li>- HBV DNA level <q>≥10,000 IU/mL</q>.</li><li>- ALT <q>≥5 x ULN</q>.</li><li>- Total bilirubin <q>>2.5 mg/dL</q>.</li><li>- Any symptom of hepatic decompensation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Evidence & Rationale</strong></summary>
            <div>
                <ul><li>- Consensus that persons with cirrhosis should <b>never</b> stop therapy.</li><li>- RCTs show modest rates of HBsAg loss after stopping (<q>~10.6%</q> at 2 years) but substantial risks.</li><li>- Risks include ALT flares (<q>26.9%</q> at 2 years) and need for re-treatment (<q>42%</q> at 5 years).</li><li>- The best predictor for successful discontinuation is a quantitative HBsAg level <q><100 IU/mL</q> at the end of treatment.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PICO Question 6: HCC Surveillance in Special Populations</strong></summary>
            <div>
                <ul><li>- <b>Question:</b> Should individuals with CHB who cleared HBsAg or have co-infections (HCV, HDV, HIV) receive HCC surveillance?</li></ul>
                
        <details>
            <summary><strong>Recommendations & Evidence</strong></summary>
            <div>
                <ul><li>- Surveillance method: Ultrasound and serum AFP every <q>6 months</q>.</li></ul>
                
        <details>
            <summary><strong>After HBsAg Loss (Rec. 6)</strong></summary>
            <div>
                <ul><li>- <b>Suggest continued surveillance for those with:</b></li><li>- Cirrhosis</li><li>- Family history of HCC</li><li>- Men who lost HBsAg after age <q><b>40</b></q></li><li>- Women who lost HBsAg after age <q><b>50</b></q></li><li>- <b>Strength:</b> Conditional; <b>Certainty:</b> Very Low.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>HBV-HDV Co-infection (Rec. 7)</strong></summary>
            <div>
                <ul><li>- <b>Suggest HCC surveillance for all adults</b>, independent of cirrhosis status.</li><li>- Decision for children should be individualized.</li><li>- <b>Rationale:</b> HCC incidence is significantly higher (<q>18.65</q> vs <q>4.84</q> per 1,000 person-years) compared to HBV mono-infection, even without cirrhosis.</li><li>- <b>Strength:</b> Conditional; <b>Certainty:</b> Very Low.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>HBV-HIV Co-infection (Rec. 8)</strong></summary>
            <div>
                <ul><li>- <b>Suggest HCC surveillance for:</b></li><li>- Men <q><b>≥18 years</b></q> of age</li><li>- Women <q><b>≥40 years</b></q> of age</li><li>- <b>Rationale:</b> Risk is higher in men and increases with age.</li><li>- <b>Strength:</b> Conditional; <b>Certainty:</b> Very Low.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>HBV-HCV Co-infection (Rec. 9)</strong></summary>
            <div>
                <ul><li>- <b>Recommend treatment for HCV.</b></li><li>- SuggestHCC surveillance as per criteria for HBV mono-infection.</li><li>- <b>Rationale:</b> After HCV cure with DAA therapy, HCC risk is expected to be similar to that of HBV mono-infection.</li><li>- <b>Strength:</b> Conditional; <b>Certainty:</b> Very Low.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Implementation Considerations</strong></summary>
            <div>
                <ul><li>- For triple/quadruple infections (HBV + HIV, HDV, HCV), surveillance should follow the recommendation for the coinfection with the <b>highest associated risk</b> (e.g., HBV-HDV).</li><li>- For prior HCV infection (anti-HCV positive, HCV RNA negative), surveillance is the same as for HBV alone.</li><li>- For prior HDV infection (anti-HDV positive, HDV RNA negative), surveillance is the same as for HBV alone.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Limitations & Research Gaps</strong></summary>
            <div>
                <ul><li>- Most recommendations have <b>low or very low certainty of evidence</b>, highlighting the need for higher quality data.</li></ul>
                
        <details>
            <summary><strong>Nomenclature Harmonization Needed</strong></summary>
            <div>
                <ul><li>- Terminology for phases of CHB infection.</li><li>- Defining upper limits of normal (ULN) for ALT in adults and children.</li><li>- Consensus on 'indeterminate' vs 'grey zone' terminology.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Topics Covered in 2018 AASLD Guidance (Unchanged)</strong></summary>
            <div>
                <ul><li>- This guideline updates specific topics; the 2018 guidance remains applicable for many areas.</li></ul>
                
        <details>
            <summary><strong>Key Unchanged Topics</strong></summary>
            <div>
                <ul><li>- Treatment of children.</li><li>- Treatment of immune active CHB (HBeAg-positive & negative) with ALT >2x ULN.</li><li>- Management of suboptimal response (low-level viremia, breakthrough) (See Figure 4).</li><li>- Treatment of persons with cirrhosis (See Figure 5).</li><li>- Management in special populations (transplant recipients, acute HBV).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Unaddressed & Controversial Topics</strong></summary>
            <div>
                <ul><li>- Several topics were not addressed in this focused update.</li></ul>
                
        <details>
            <summary><strong>Future Topics for Guidance</strong></summary>
            <div>
                <ul><li>- Role of newer biomarkers: HBsAg quantitation, HBV RNA, HBcrAg.</li><li>- Treatment of inactive carriers with high HBsAg levels (<q>>1000 IU/mL</q>).</li><li>- Role of peginterferon add-on or switch therapy to achieve functional cure.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Comparison with WHO Guideline</strong></summary>
            <div>
                <ul><li>- <b>AASLD:</b> Continues to use HBeAg status and multiple HBV DNA thresholds.</li><li>- <b>WHO:</b> Excludes HBeAg status and uses a single HBV DNA threshold (<q>>2000 IU/mL</q>).</li><li>- This difference reflects easier access to comprehensive lab testing in the U.S.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Plans for Updating</strong></summary>
            <div>
                <ul><li>- Uncovered topics will be addressed in future guideline documents.</li><li>- Updated guidelines are anticipated as new therapies focused on <b>functional cure</b> become FDA-approved.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
